MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Behavioral abnormalities"

  • 2023 International Congress

    Diffusion imaging study of mild behavioral impairment in Parkinson’s disease.

    H. Almgren, M. Descoteaux, M. Ghahremani, Z. Ismail, O. Monchi (Calgary, Canada)

    Objective: Patients with Parkinson’s disease (PD) experience changes in behavior, personality, and cognition. Mild Behavioral Impairment (MBI) is a validated neurobehavioral syndrome that identifies a…
  • 2023 International Congress

    Therapeutic effects of citral nanoliposome on Parkinson’s treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways

    N. Moradikor, M. Haghipanah, W. Mohamed (Tbilisi, Georgia)

    Objective: The present study aimed to assess the effects of citral nanoliposome on Parkinson's treatment in a rat model. Background: Parkinson's disease is the most…
  • 2023 International Congress

    Severe movement disorder initially suspected of being conversion – key insights from the psychiatrist

    L. Jaffe (Honolulu, USA)

    Objective: The review of a case diagnosed as Conversion Disorder (CD) in a University Movement Disorders clinic is presented here.  As this patient eventually recovered…
  • 2023 International Congress

    Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson’s disease

    M. Ruitenberg, E. Whooley, H. Macdonald, V. Koppelmans (Leiden, Netherlands)

    Objective: To assess the interplay of polygenic dopamine risk scores and psychiatric symptoms in the development of impulse control disorders (ICDs) in de novo patients…
  • 2023 International Congress

    Self-report vs. informant-report of problematic behaviors using the Huntington’s Disease-Behavioral Questionnaire

    S. Hughes, E. Churchill, G. Parkin, B. Culbert, A. Smirnova, A. Hall, P. Gilbert, J. Corey-Bloom (San Diego, USA)

    Objective: To examine the utility of a new behavioral measure, the Huntington’s Disease–Behavioral Questionnaire (HD-BQ) (Hughes et al, 2023), in individuals with Huntington’s disease (HD).…
  • 2023 International Congress

    Impact of dopamine replacement therapy on shame in Parkinson’s disease patients

    S. Catalano Chiuvé, D. Benis, A. Zulet, P. Krack, V. Fleury (Geneva, Switzerland)

    Objective: This study aims to investigate the effect of dopaminergic replacement therapy (DRT) on shame using emotional dynamic rating scales during ON and OFF-DRT states.…
  • 2023 International Congress

    Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease

    E. Furr Stimming, S. Abdollah Zadegan, J. Patino, N. Rocha (Houston, USA)

    Objective: To prove the efficacy and safety of dextromethorphan/quinidine 20mg/10mg (Nuedexta®) in patients with irritability due to HD. Background: Irritability is one of HD's most…
  • 2023 International Congress

    Needs and priorities of people with Parkinson’s and care partners regarding neuropsychiatric symptoms

    J. Goldman, H. Peirce, D. Merkitch (Chicago, USA)

    Objective: To examine the experiences of people with Parkinson’s disease (PD) and care partners (CPs) regarding cognitive, mood, behavioral, and sleep issues. Background: Neuropsychiatric symptoms…
  • 2022 International Congress

    Chikungunya: An emerging arthropod borne disease presenting as rhombencephalitis with near complete recovery

    M. Shah, P. Shah, T. Singhal, K. Shetty, R. Syed, A. Aggarwal (Mumbai, India)

    Objective: To report the clinical course and good neurological outcome of severe Chikungunya rhombencephalitis. Background: Chikungunya is an emerging Aedes mosquito borne virus that is…
  • 2022 International Congress

    FACIAL EMOTION EXPRESSIVITY IN PARKINSON’S AND ALZHEIMER’S DISEASES

    A. Cannavacciuolo, A. Guerra, D. Colella, M. Salzillo, A. de Biase, G. Paparella, M. Canevelli, G. Bruno, A. Berardelli, M. Bologna (Pozzilli, Italy)

    Objective: We here aimed to comprehensively investigate facial emotion expressivity in Parkinson’s disease (PD) and Alzheimer’s disease (AD) patients compared to healthy controls (HCs). Background:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley